Abstract
Ultrasensitive assay technologies have enabled the measurement of low-abundant blood-based biomarkers of neurodegenerative diseases. They reduce the need for invasive CSF sample collection, streamline sample acquisition and screening, and empower the study of the transitions from health to disease.
Neurofilament light chain (NF-L) is a valuable biomarker for assessing the progression and treatment of Alzheimer’s Disease, Multiple Sclerosis, and Huntington’s Disease and is under investigation as a potential biomarker for several other neurological disorders.
Watch this webinar to learn how ultrasensitive Single Molecule Counting (SMC®️) technology enables measurements of this low-abundant blood-based neurodegeneration biomarker.
You’ll discover how the assay helps researchers investigate neurodegenerative conditions and neurological injury with consistent and reliable measurement of NF-L at sub-pg/mL concentrations in human blood and CSF samples.
In this webinar, you will learn about:
- Why NF-L is emerging as a critical blood-based neurodegenerative biomarker
- The challenges with measuring low-abundant biomarkers
- How SMC®️ technology was used to develop assays for easy and sensitive detection of low-abundant blood-based biomarkers
For Research Use Only. Not For Use In Diagnostic Procedures.
Speakers
Rick Wiese
Merck
Head of Singleplex & Special Protein Platforms R&D
Rick Wiese holds a PhD from FDA NCTR and has over 22 years of experience in immunoassay development and production. In 2007, he became R&D Manager for the MILLIPLEX® assay group and then moved to Operations as Senior Manager, Upstream Operations in 2013, working extensively on product and process engineering projects for immunoassay products. In 2021, Rick moved back to R&D as Head of Singleplex & Special Protein Platforms R&D.
Protein biology
- Protein quantitation
Duração:40min
Idioma:English
Sessão 1:apresentado August 30, 2022
Para continuar lendo, faça login ou crie uma conta.
Ainda não tem uma conta?